#USA #Lexington, Kentucky #Piramal Pharma #ADCelerate #Piramal Solutions

Piramal Pharma Solutions Unveils $90 Million Expansion Plan

In a significant stride towards enhancing its production capabilities, Piramal Pharma Solutions has recently broken ground on a substantial $90 million expansion initiative at two of its facilities in the United States. This major investment is pivotal for the company's integrated offerings in antibody-drug conjugates (ADC), particularly their ADCelerate™ product line. The groundbreaking ceremony took place on June 25, 2025, in Lexington, Kentucky, marking a crucial milestone for the business.

Purpose of the Expansion

The expansion aims to bolster the production capacity of Piramal Pharma's capabilities in commercial-scale manufacturing. The facilities being upgraded are essential components of Piramal's ADC offering, showcasing the company's commitment to delivering innovative solutions that meet patient needs effectively. As demand for drug production grows, this investment is timely, reflecting a burgeoning market in injectable medications fueled by increased healthcare demands and evolving regulatory approvals.

The Riverview, Michigan site provides comprehensive drug development and manufacturing services, particularly for highly potent active pharmaceutical ingredients (HPAPIs). The expansion will see the introduction of a commercial facility dedicated to the development and manufacture of payload-linkers necessary for ensuring the safety and efficacy of ADC therapies. This new facility is expected to be operational by the end of 2025.

Meanwhile, the Lexington, Kentucky facility, specialized in sterile compounding and filling operations, is set to receive a significant upgrade, adding approximately 24,000 square feet of manufacturing space, a new laboratory, and state-of-the-art equipment. This includes a new filling line, two large-scale lyophilizers, a specialized closure machine, and an external vial-washing facility. The completion of this expansion is projected for late 2027.

Economic Impact and Community Engagement

As part of this expansion, Piramal Pharma anticipates creating 40 new full-time positions in the Lexington area, which will not only boost the local economy but also solidify the company's workforce. Company officials emphasized their commitment to working with local partners to leverage regional strengths, thus driving future innovations.

Local leaders, including Lexington Mayor Linda Gorton, expressed their enthusiasm for Piramal's commitment to expanding in the area. The mayor noted the significance of Piramal's investment, highlighting Lexington's potential as a hub for the pharmaceutical industry, aided by the presence of top-tier pharmaceutical programs at local educational institutions.

Current Industry Trends

This strategic investment comes at a time when the sterile injectable market is expected to exceed $20 billion by 2028, driven by heightened medical needs and advancements in scientific research. Furthermore, the rising popularity of ADC therapies marks an intensified demand for enhanced manufacturing capacities to address the evolving needs in patient care.

Nandini Piramal, Chairperson of Piramal Pharma, stated, “Our commitment transcends just business growth; it’s about catering to patient needs and addressing the healthcare challenges of today. We are poised to meet the increasing demand for sterile injectables and ADC therapies.”

Peter DeYoung, CEO of Piramal Global Pharma, reinforced this sentiment, emphasizing the company’s adaptability to market changes. He remarked, “With the rise of ADCs as an effective class of precision immunotherapies, our investment and expansion are aligned with growing patient needs and prescriber trends. We are committed to enhancing our services and expanding our ADCelerate™ capabilities.”

Conclusion

Overall, the $90 million expansion initiative by Piramal Pharma Solutions not only represents a substantial advancement in the company’s manufacturing capabilities but also underscores its overarching commitment to patient-centric healthcare delivery. As the company plans for the future, it remains focused on ensuring quality and accessibility in drug development and production, thereby securing a better future for patients and the communities they serve.

For further inquiries and information, you can follow Piramal Pharma Solutions on their LinkedIn or Facebook pages.